Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials Hub In Singapore

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, recently announced that it will invest $4.6M to further expand its Singapore clinical supply facility by building new flexible GMP space for secondary packaging, doubling its ambient storage space, and quadrupling cold storage capacity. The continued expansion of the site will support global and regional customers’ growth in clinical trials activity in the Asia–Pacific region.

Established in 1998, Catalent’s Singapore site now provides full clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import/export management, Importer of Record (IoR) service, and full returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.

“Our Singapore facility is fully approved by the Health Science Authority for GMP across all its activities,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services. “Customer demand at the site has increased by 30% over last year, and this expansion, coupled with our recently announced opening of a facility in Japan, will allow Catalent to better support multinational customers’ growing trial’s needs, while providing more flexible solutions for local customers in the region.”

With facilities in the US, UK, Germany, Japan and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.

For more information on Catalent’s Clinical Supply services, please visit: www.catalent.com/clinical

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8B in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.